[Expert consensus on the application of irinotecan liposomes in digestive system tumors (2025 edition)]

Gastrointestinal cancers are common malignant tumors posing a serious threat to human health. Irinotecan liposome, a recently approved chemotherapeutic agent primarily indicated for pancreatic cancer within the gastrointestinal malignancies, has seen the publication of numerous high-quality clinical studies with high levels of evidence over the past two years. Scholars continue to explore new clinical applications for this agent. To standardize the clinical application of irinotecan liposomes in gastrointestinal cancers, this expert consensus was developed through multiple rounds of drafting and review led by several specialized committees of the Chinese Anti-Cancer Association, with reference to relevant domestic and international guidelines and the latest evidence-based medical data. This consensus aims to promote rational clinical drug use, prolong patient survival, and provide guidance for the clinical management of gastrointestinal cancers by standardizing chemotherapy regimens, optimizing treatment strategies, and managing adverse events. It details the clinical application strategies, supporting evidence, and adverse event management of irinotecan liposomes in pancreatic, biliary tract, colorectal, and gastric cancers. Furthermore, the consensus addresses key contentious issues-including, but not limited to, dosage, administration, combination therapies, and adverse event management-through expert voting within the oncology field. These deliberations formed the basis for the consensus recommendations provided herein for the reference of clinical practitioners.